Answers are grounded in this paper and cite their sources.
Background/Objectives: Periodontal disease ranks among the most widespread chronic inflammatory ailments affecting human populations globally. Berberine exerts antimicrobial, anti-inflammatory and bone-protective effects, and accumulating preclinical evidence implies its therapeutic potential for periodontal disease. This meta-analysis intended to offer a systematic quantitative evaluation regarding the therapeutic effects of berberine in animal-based periodontal disease experiments, providing preclinical evidence for its clinical translation. Methods: Seven electronic databases were consulted to implement the systematic literature retrieval. Original in vivo animal studies investigating the effects of berberine on experimental periodontal disease models were included. The SYRCLE tool was used to appraise the risk of bias across eligible animal studies. All statistical analyses were performed using RevMan 5.4 and Stata 15.1. Results: Systematic database searching retrieved 579 records, among which 15 proved eligible for meta-analysis. Pooled analyses demonstrated that berberine significantly attenuated alveolar bone resorption in periodontal disease animal models (SMD = −3.21; 95% CI, −5.05 to −1.37; p < 0.01). Berberine likewise decreased counts of Tartrate-Resistant Acid Phosphatase (TRAP)-positive osteoclasts and suppressed the expression of pro-inflammatory cytokines. Berberine improved several bone microarchitecture and inflammatory outcomes, while the increases in BV/TV, Tb.N, and IL-10 did not reach statistical significance. Sensitivity analyses supported the robustness of the pooled estimates. Nevertheless, methodological limitations were prevalent among the included studies. Funnel plot asymmetry suggestive of potential publication bias was observed for TNF-α and IL-1β, and substantial heterogeneity was observed for several outcome measures. Conclusions: Berberine may represent a potential candidate for further preclinical investigation based on current preclinical evidence. However, limitations related to methodological quality, heterogeneity, and publication bias merit further exploration via rigorously designed standardized animal experiments and high-quality clinical trials.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: